Pfizer Inc.

NYSE:PFE   3:59:58 PM EDT
52.32
-0.11 (-0.21%)
Products, Earnings Announcements

Pfizer Reports Additional Data On Paxlovid Supporting Upcoming New Drug Application Submission To U.S. FDA

Published: 06/14/2022 20:53 GMT
Pfizer Inc. (PFE) - Pfizer Reports Additional Data on Paxlovid Supporting Upcoming New Drug Application Submission to U.S. FDA.
Pfizer - Data From Standard-risk Patients Will Be Included in Upcoming NDA Submission to U.S. FDA for High-risk Patients.
Pfizer -in Epic-sr Study of Paxlovid, Novel Primary Endpoint of Self-reported, Sustained Alleviation of All Symptoms for 4 Consecutive Days Was Not Met.
Pfizer - in Epic-sr Study, Non-significant 70% Relative Risk Reduction Was Observed in Key Secondary Endpoint of Hospitalization Or Death.
Pfizer - Co to Cease Enrollment Into the Epic-sr Trial Due to Low Rate of Hospitalization Or Death in Standard-risk Population.
Pfizer - in Epic-sr, Treatment With Paxlovid Showed Nominally Significant 62% Decrease in Covid-19-related Medical Visits per Day Across Patients.
Pfizer - Co Will Focus Efforts on Generating Further Data on Paxlovid in Vulnerable Populations.
Pfizer - Other Not Statistically Significant Findings From Epic-sr Include No Deaths in Patients Who Received Paxlovid.
Pfizer - Data From Standard-risk Patients Are Supportive of Efficacy Data Observed in Epic-hr Study.
Pfizer - Results From Additional Analyses Are Not Expected to Impact Pfizer’s Full-year 2022 Revenue Guidance.
Pfizer - Other Not Statistically Significant Findings From Epic-sr Include No Paxlovid-treated Patients Admitted to Icu Versus 3 in Placebo Group.
Further Company Coverage: Pfen ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $25.45 Billion
Adjusted EPS is expected to be $1.79

Next Quarter Revenue Guidance is expected to be $25.7 Billion
Next Quarter EPS Guidance is expected to be $1.89

More details on our Analysts Page.